[{"id":"160a70b8-6f49-4ee1-ba97-f6f7d4157dc6","acronym":"","url":"https://clinicaltrials.gov/study/NCT03216499","created_at":"2021-01-18T15:52:16.143Z","updated_at":"2025-02-25T16:06:33.407Z","phase":"Phase 2","brief_title":"HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma","source_id_and_acronym":"NCT03216499","lead_sponsor":"Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins","biomarkers":" MGMT","pipe":"","alterations":" ","tags":["MGMT"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e MK-3795"],"overall_status":"Completed","enrollment":" Enrollment 24","initiation":"Initiation: 09/14/2017","start_date":" 09/14/2017","primary_txt":" Primary completion: 08/31/2019","primary_completion_date":" 08/31/2019","study_txt":" Completion: 06/05/2020","study_completion_date":" 06/05/2020","last_update_posted":"2022-05-09"}]